Soleus Capital Management’s SAB Biotherapeutics SABS Stock Holding History
Bought
Maintained
Sold
Other funds holding SABS
Soleus Capital Management's SABS Position: Q3 2026 in Review
Soleus Capital Management reduced its SAB Biotherapeutics (SABS) stake by 25% in Q3 2026, selling an estimated $829K and leaving 672,039 shares worth $2.13M. The position accounts for 0.08% of the portfolio, ranked #76.
Soleus Capital Management first reported a position in SABS in Q1 2026 and has held it in 3 quarters since. The position peaked at $4.02M in Q1 2026. 100 funds tracked by Wall St. Rank hold SABS as of Q3 2026.
- Soleus Capital Management held 672,039 shares of SAB Biotherapeutics worth $2.13M as of Q3 2026.
- Soleus Capital Management sold 227,961 SAB Biotherapeutics shares in Q3 2026, an estimated $829K.
- SAB Biotherapeutics made up 0.08% of Soleus Capital Management's portfolio in Q3 2026, its #76 holding.
- Soleus Capital Management first reported a position in SAB Biotherapeutics in Q1 2026 and has held it in 3 quarters since.
- Soleus Capital Management's SAB Biotherapeutics position peaked at $4.02M in Q1 2026.
- 100 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.
Based on Soleus Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.